45 Lenvatinib for endometrial cancer: reducing healthcare disparities and emphasizing equitable medication access through quality improvement
Objectives: Combination pembrolizumab with lenvatinib (len/pem) has revolutionized second-line treatment and survival outcomes for patients with mismatch repair-proficient (MMRp) recurrent endometrial cancer (EC). We sought to define existing barriers to medication access and, through quality improv...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Elsevier,
2023-06-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |